FDA Approves J&J's (JNJ) Zytiga; Dendreon (DNDN) Shares Volatile Following Announcement
Tweet
Share
E-mailGet Alerts JNJ Hot Sheet
Join SI Premium – FREE
The FDA has announced approval of J&J's (NYSE: JNJ) abiraterone acetate for prostate cancer Thursday afternoon. The product will be sold under the name Zytiga.
Traders are attributing a recent move lower in shares of Dendreon (Nasdaq: DNDN) to the Johnson & Johnson approval.
Traders are attributing a recent move lower in shares of Dendreon (Nasdaq: DNDN) to the Johnson & Johnson approval.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler: PFA survey is most positive for Medtronic, Inc. (MDT)
- DOJ, TikTok settle for $400m in children's privacy suit - Axios
- Citadel has shed over 80% of aggregate risk from Situational Awareness portfolio - CNBC
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
